

REMARKS

Applicants gratefully acknowledge the Examiner's indication that claims 1-3 and 10 are allowable. Claims 1-11 and 19-55 are now presented for the Examiner's review and consideration. Claims 12-18 have been canceled without prejudice. Claims 1-11 and 19-55 are fully supported by the application as filed and there is thus no issue of new matter; entry of this Amendment is therefore requested at this time.

Support for Amended Claims 3-9, 11, and New Claims 19-55

Support for claims 3-9, 11, and 19-55 is found *inter alia* with claims 1-11 as filed. The amendments to claims 3-9 and 11 have been made, and claims 19-55 have been added to remove the multiple dependencies in claims 3-9 and 11 as filed.

Section 112 Fifth Paragraph Rejections

The Examiner has rejected claims 4-9 and 11 under 35 U.S.C. § 112 fifth paragraph as being dependent from multiply dependent claims.

Amendments to claims 4-9 and 11 have removed the multiple dependencies from these claims, rendering the Examiner's rejection moot. Applicants respectfully request the Examiner to withdraw his rejection of claims 4-9 and 11.

Conclusion

For all of the reasons above, claims 1-11 and 19-55 are believed to be in condition for allowance, early notice of which would be appreciated. If the Examiner does not agree that all claims are allowable, then a telephonic or in-person interview is respectfully requested to discuss any remaining issues and accelerate the eventual allowance of this application.

No fee is believed to be due with this response. Authorization is hereby given to charge all required fees to Johnson & Johnson Deposit Account No. 10-0750/JAB-1409/MBZ.

Respectfully submitted,

By:  45,257
Matthew B. Zisk Reg. No

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1287
Dated: July 15, 2002



VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. A compound as claimed in claim 1 [or 2] wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents.
4. A compound as claimed in [any one of] claim[s] 1 [to 3 provided that those compounds] wherein X is a direct bond, at least one of R^3 and R^4 is hydrogen, and R^2 is 3-pyridinyl optionally substituted in the 6 position with an optionally substituted alkyl or acyl group are excluded.
5. A compound as claimed in [any one of] claim[s] 1 [to 4] wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents.
6. A compound as claimed in [any one of] claim[s] 1 [to 5] wherein R^2 is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het^2 , R^{11} and $C_{1-4}alkyl$ optionally substituted with Het^2 or R^{11} .
7. A compound as claimed in [any one of] claim[s] 1 [to 6] wherein R^3 and R^4 are both methyl and $-X-R^2$ is Het^1 .
8. A compound as claimed in [any one of] claim[s] 1 [to 7] wherein p is 1 or 2 and each R^1 is chloro.
9. A compound as claimed in [any one of] claim[s] 1 [to 8] wherein R^3 and R^4 are both methyl, $-X-R^2$ is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents, and p is 2 whereby both R^1 substituents are chloro positioned ortho relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents.
11. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in [any one of] claim[s] 1 [to 10].

B

19. A compound as claimed in claim 2 wherein X is a direct bond, at least one of R³ and R⁴ is hydrogen, and R² is 3-pyridinyl optionally substituted in the 6 position with an optionally substituted alkyl or acyl group are excluded.
20. A compound as claimed in claim 3 wherein X is a direct bond, at least one of R³ and R⁴ is hydrogen, and R² is 3-pyridinyl optionally substituted in the 6 position with an optionally substituted alkyl or acyl group are excluded.
21. A compound as claimed in claim 2 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
22. A compound as claimed in claim 3 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
23. A compound as claimed in claim 4 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
24. A compound as claimed in claim 2 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.
25. A compound as claimed in claim 3 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.
26. A compound as claimed in claim 4 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three

substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.

27. A compound as claimed in claim 5 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.
28. A compound as claimed in claim 2 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
29. A compound as claimed in claim 3 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
30. A compound as claimed in claim 4 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
31. A compound as claimed in claim 5 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
32. A compound as claimed in claim 6 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
33. A compound as claimed in claim 2 wherein p is 1 or 2 and each R¹ is chloro.
34. A compound as claimed in claim 3 wherein p is 1 or 2 and each R¹ is chloro.
35. A compound as claimed in claim 4 wherein p is 1 or 2 and each R¹ is chloro.
36. A compound as claimed in claim 5 wherein p is 1 or 2 and each R¹ is chloro.
37. A compound as claimed in claim 6 wherein p is 1 or 2 and each R¹ is chloro.
38. A compound as claimed in claim 7 wherein p is 1 or 2 and each R¹ is chloro.
39. A compound as claimed in claim 2 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para

position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents, and p is 2 whereby both R^1 substituents are chloro positioned ortho relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents.

40. A compound as claimed in claim 3 wherein R^3 and R^4 are both methyl, $-X-R^2$ is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents, and p is 2 whereby both R^1 substituents are chloro positioned ortho relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents.

41. A compound as claimed in claim 4 wherein R^3 and R^4 are both methyl, $-X-R^2$ is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents, and p is 2 whereby both R^1 substituents are chloro positioned ortho relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents.

42. A compound as claimed in claim 5 wherein R^3 and R^4 are both methyl, $-X-R^2$ is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents, and p is 2 whereby both R^1 substituents are chloro positioned ortho relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents.

43. A compound as claimed in claim 6 wherein R^3 and R^4 are both methyl, $-X-R^2$ is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents, and p is 2 whereby both R^1 substituents are chloro positioned ortho relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents.

44. A compound as claimed in claim 7 wherein R^3 and R^4 are both methyl, $-X-R^2$ is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents, and p is 2 whereby both R^1 substituents are chloro positioned ortho relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents.

45. A compound as claimed in claim 8 wherein R^3 and R^4 are both methyl, $-X-R^2$ is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the $-X-R^2$, R^3 and R^4 substituents, and p is 2

whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.

46. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 2.
47. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 3.
48. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 4.
49. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 5.
50. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 6.
51. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 7.
52. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 8.
53. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 9.
54. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 10.
55. A compound as claimed in claim 2 wherein the compound of formula (I) contains an ester function.